Detalles de la búsqueda
1.
Frequency of genetic alterations differs in advanced breast cancer between metastatic sites.
Genes Chromosomes Cancer;
63(1): e23199, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37672607
2.
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.
Mod Pathol;
37(7): 100497, 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38641322
3.
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Mod Pathol;
36(4): 100100, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788081
4.
Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study.
Histopathology;
83(5): 810-821, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37609779
5.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol;
23(5): 625-635, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405088
6.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res;
24(1): 58, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056374
7.
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer;
126(12): 1715-1724, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35194193
8.
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Mod Pathol;
35(12): 1804-1811, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842479
9.
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.
Mod Pathol;
35(12): 1812-1820, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35922548
10.
Transcription factor AP-2beta in development, differentiation and tumorigenesis.
Int J Cancer;
149(6): 1221-1227, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33720400
11.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer;
148(10): 2614-2627, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533487
12.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res;
22(1): 47, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32408905
13.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer;
146(1): 262-271, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31162838
14.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer;
126(22): 4847-4858, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780421
15.
E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
Mod Pathol;
33(12): 2483-2498, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572153
16.
ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Genes Chromosomes Cancer;
58(3): 175-185, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520184
17.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat;
175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
18.
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
J Pathol;
245(3): 373-383, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29708279
19.
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2ß.
Lab Invest;
98(1): 117-129, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29035379
20.
Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast.
Mod Pathol;
36(5): 100163, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36965702